Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

• Status: Active, not recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Criteria

Inclusion Criteria:

• acute myeloid leukemia (CR1 or CR2) or myelodysplasia syndrome

• patients with HLA matched sibling, unrelated or Haplo-identical donor

Exclusion Criteria:

• patients with active infection

• patients with abnormal liver function damage: ALT/AST above 2X normal range

• patients with abnormal renal function damage Scr>160µmol/L;

• patients with insufficient pulmonary function (FEV1，FVC，DLCO<50%）and heart failure or with EF <50%)

• patients with mental instability or unwilling to give inform consent